National HealthCare Co. (NYSE:NHC - Get Free Report) VP Timothy J. Shelly sold 614 shares of the business's stock in a transaction on Friday, December 13th. The shares were sold at an average price of $121.44, for a total transaction of $74,564.16. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
National HealthCare Stock Performance
Shares of NHC traded down $3.49 during trading hours on Monday, hitting $103.31. The company's stock had a trading volume of 56,590 shares, compared to its average volume of 54,563. The company has a market cap of $1.60 billion, a price-to-earnings ratio of 12.95 and a beta of 0.43. The business has a 50 day simple moving average of $120.84 and a two-hundred day simple moving average of $122.45. National HealthCare Co. has a 52-week low of $87.03 and a 52-week high of $138.49. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.80 and a quick ratio of 1.77.
National HealthCare Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Monday, December 30th will be issued a $0.61 dividend. This represents a $2.44 dividend on an annualized basis and a dividend yield of 2.36%. The ex-dividend date is Monday, December 30th. National HealthCare's payout ratio is currently 30.58%.
Hedge Funds Weigh In On National HealthCare
Large investors have recently bought and sold shares of the stock. GAMMA Investing LLC lifted its holdings in National HealthCare by 35.5% in the third quarter. GAMMA Investing LLC now owns 313 shares of the company's stock worth $39,000 after buying an additional 82 shares during the period. Copeland Capital Management LLC bought a new position in shares of National HealthCare in the third quarter worth approximately $62,000. Reliant Investment Management LLC purchased a new stake in National HealthCare during the 3rd quarter valued at $203,000. Ballentine Partners LLC bought a new position in National HealthCare during the 3rd quarter valued at about $223,000. Finally, Marshall Wace LLP purchased a new stake in National HealthCare in the second quarter worth approximately $228,000. 56.44% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Separately, StockNews.com raised shares of National HealthCare from a "buy" rating to a "strong-buy" rating in a report on Saturday, November 16th.
Check Out Our Latest Analysis on NHC
About National HealthCare
(
Get Free Report)
National HealthCare Corporation engages in the operation of services to skilled nursing facilities, assisted and independent living facilities, homecare and hospice agencies, and health hospitals. Its skilled nursing facilities offer licensed therapy services, nutrition services, social services, activities, and housekeeping and laundry services, as well as medical services prescribed by physicians; and rehabilitative services, such as physical, speech, respiratory, and occupational therapy for patients recovering from strokes, heart attacks, orthopedic conditions, neurological illnesses, or other illnesses, injuries, or disabilities.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider National HealthCare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and National HealthCare wasn't on the list.
While National HealthCare currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.